Protocol, and synopsis: •Modification of the delay between the baseline assessments and inclusion in Part 1, going from 7 days to 28 days. The biological assessment must be carried out within 7 days before the start of treatment. •Modification of gynecological monitoring: it will not be requested at each visit during the treatment cycles: these examinations must be carried out at baseline, before the start of Part 2 and at the end of the study (at the end of treatment) and when necessary •Pregnancy tests: this test remains necessary at baseline for validation of inclusion, it will then no longer be carried out automatically and mandatory at other times of the study, because the sterilizing effect of radiotherapy is recognized. •Modification of an inclusion criterion for Part 2: “Patients who received chemotherapy + concomitant boost on macroscopic lymph nodes” modified by “Patients who received chemotherapy that can be associated with a concomitant boost on macroscopic lymph nodes.” » Because not all patients will receive this boost since it depends on the presence or not of lymph nodes visible macroscopically on the PET scan. •Concomitant treatments: it is added that treatment with EPO is not recommended. •Modification of an inclusion criterion for Part 2: “Patients who received chemotherapy + concomitant boost on macroscopic lymph nodes” is replaced by “Patients who received chemotherapy that can be associated with a concomitant boost on macroscopic lymph nodes.” », because not all patients will receive this boost since it depends on the presence or not of lymph nodes visible macroscopically on the PET scan •Concomitant treatments: it is added that treatment with EPO is not recommended. Trial site list: •Declaration of 3 new investigators for site n°1 (Centre Oscar Lambret, Lille) Informed consent form: •Conduct of the study: modification of the duration of the assessment planned for inclusion in Part 1, going from 7 days

• Temporary halt of inclusions on 27-MAR-2020 due to the health situation linked to Covid-19 • Restart of inclusions on 26-MAY-2020 in the conditions prior to the transitional measures linked to Covid-19

Trial site list: • Declaration of a new investigator for site n°1 (Centre Oscar Lambret, Lille) • Addition of a 6th trial site: Lens Hospital Center, represented by Dr. FOURQUET as principal investigator

Protocol, and synopsis: • Addition of recommendations linked to the anti-COVID vaccine strategy Trial site lists: •Declaration of a new investigator for site n°2 (Centre Léonard de Vinci) SmPC PACLITAXEL 6mg/ml: •Update of the document (version of 14-JUNE-2021), with the description of a new adverse event of undetermined frequency: palmoplantar erythrodysesthesia which may persist beyond 6 months after stopping treatment. This modification has an impact on the expected/unexpected nature of the SARs and the conduct of the study; it is therefore considered substantial but does not require an update of the protocol (this already specifies the action to be taken in the event of peripheral neuropathies) nor the informed consent form given to patients (which already includes the list of frequent and very frequent adverse effects)

Protocol, and synopsis: •Extension of the recruitment period by 6 months and update of the study schedule. The duration of exposure to the investigational drug is not extended, the definition of the end of the trial and the monitoring conditions are unchanged. At the end of this extension, the study will be definitively closed to recruitment. Protocol: •Compliance of the protocol with the SPC of paclitaxel dated 04-MAR-2021: addition of new contraindicated combinations with paclitaxel Informed consent form: •Information on the recruitment period is deleted because it is calculated on the total number of patients initially expected, however, the objective is now to reach 50% of inclusions (23 patients) by 30-JUNE-2023. •Information on the delay necessary to obtain results is also removed, for the same reasons as above. •Addition of a safety instruction related to the contraceptive method. •Addition of a paragraph to allow the reuse of data for other research (retrospective cohorts, etc.) •Update of the CNIL URL to allow patients to send a complaint to the CNIL; the postal address is also specified SmPC PACLITAXEL 6mg/ml •Update of the document (version of 04-MAR-2021). Some of the modifications have an impact on the list of concomitant treatments to avoid •Addition of contraindicated combinations of palitaxel with St. John's wort, live attenuated vaccines; •Addition of associations not recommended with new enzyme inducers not described in the previous version of the SPC) and fosphenytoin).

Protocol and synopsis: •The follow-up of patients is interrupted on 31-JAN-2025 (=LPLV) •Addition of a paragraph regarding the modification of the end of the trial, and its justification •Compliance of the duration of follow-up with the end of the study New document: •Introduction of a new letter to inform patients of the end of the study Insurance: •The insurance certificate is updated following the new definition of end of study Note: This substantial amendment was released for information to regulatory authorities since the trial had already been completed, and because the platform for submitting amendments to the french Ethics Committee (SI RIPH 2G) does not allow to submit amendment after the end of the study. However, the Ethics Committee received and examined the documents outside the usual procedure and made a comment on the information letter. All modifications requested by the Ethics Committee regarding the information letter have been made.